Savara Inc (NASDAQ:SVRA) Position Increased by Two Sigma Investments LP

Two Sigma Investments LP boosted its holdings in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 19.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 785,477 shares of the company's stock after purchasing an additional 127,628 shares during the period. Two Sigma Investments LP owned approximately 0.46% of Savara worth $2,411,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of SVRA. Vanguard Group Inc. lifted its holdings in shares of Savara by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock worth $25,512,000 after purchasing an additional 365,959 shares during the period. Deerfield Management Company L.P. Series C raised its position in Savara by 23.2% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock worth $24,449,000 after buying an additional 1,498,223 shares during the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Savara by 45.2% in the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company's stock worth $23,103,000 after acquiring an additional 2,344,308 shares during the period. Farallon Capital Management LLC boosted its holdings in shares of Savara by 49.9% in the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company's stock valued at $20,983,000 after acquiring an additional 2,275,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Savara by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company's stock worth $8,549,000 after acquiring an additional 57,187 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on SVRA shares. Wells Fargo & Company reduced their price target on Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 28th. Guggenheim reissued a "buy" rating and issued a $8.00 target price (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Evercore ISI cut their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a report on Wednesday, May 28th. Finally, HC Wainwright cut shares of Savara from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $6.00 to $2.00 in a research note on Thursday, May 29th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $7.17.

Savara Stock Up 3.8%

Shares of NASDAQ SVRA traded up $0.09 during midday trading on Wednesday, reaching $2.49. 925,078 shares of the company's stock were exchanged, compared to its average volume of 1,424,812. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a 52-week low of $1.89 and a 52-week high of $5.11. The business's fifty day moving average price is $2.89 and its two-hundred day moving average price is $2.93. The stock has a market capitalization of $430.36 million, a PE ratio of -5.79 and a beta of 0.44.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). Analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.